DISCOVERY OF A SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY (SMO4690) AS A POTENTIAL TREATMENT FOR DEGENERATIVE DISC DISEASE

Author Block: C. Barroga, V. Deshmukh, S. KC, L. Dellamary, J. Hood, J. Steward, H. Hu, Y. Yazici; Samumed, San Diego, CA

Abstract:

Purpose: Degenerative Disc Disease (DDD) is a major cause of low back pain. It is characterized by degenerative changes in the intervertebral disc, nucleus pulposus (NP), and cartilage matrix, resulting in decreased disc height and loss of shock absorption capability. Treatment of DDD is limited to pain management with analgesics, steroids or surgical procedures; no current therapy can reverse disc degeneration. Wnt signaling in disc progenitor cells potentially plays an important role in DDD by regulating degenerative changes and repair mechanisms, such as the proliferation and differentiation of resident NP cells. SMO4690, a novel, small-molecule, Wnt pathway inhibitor was evaluated in a series of preclinical studies to determine its potential to induce proliferation and differentiation of primary NP cells, thereby promoting disc healing.

Methods: Wnt pathway inhibition was measured using a cell based luciferase reporter assay controlled by a Wnt-responsive promoter. In vitro proliferation of NP cells from rat coccygeal discs, treated with vehicle or SMO4690 for 5 days, was measured by cell doubling index (CDI= cell number/initial cell number/days). Differentiation of NP cells into “chondrocyte-like” NP cells with vehicle or SMO4690 treatment for 12 days was measured by Alcian blue staining and absorbance based quantification. Pharmacokinetics were evaluated by intradiscal (ID) injection in rats and rabbits, followed by analysis of compound concentrations in the disc and plasma. In vivo efficacy following a single ID injection of SMO4690 was evaluated in a rat coccygeal intervertebral disc needle puncture model, using radiographic measurement of disk height (disc height index (DHI) = DH/vertebral height). Disc health was measured by histological scoring (total 4-16) of sections stained with Safranin O/Fast Green or Masson’s Trichrome for integrity of annulus fibrosus (AF), border between AF and NP, cellularity, and matrix of NP.

Results: SMO4690 demonstrated potent (EC50=1nM) and selective inhibition of Wnt signaling. SMO4690 induced dose-dependent proliferation of NP cells in vitro with CDI ~2 fold higher in cells treated with SMO4690 as compared to vehicle (p<0.05). Cells treated with SMO4690 also showed significantly increased Alcian blue absorbance (p<0.01), indicating differentiation to chondrocyte-like cells and production of proteoglycan components of the extracellular matrix. Single ID injection of SMO4690 resulted in disc concentrations >EC50 for >180 days, with minimal systemic exposure or toxicity, as measured by behavioral changes, animal health, and gross and microscopic morphology changes. In the in vivo rat DDD model, a single ID injection of SMO4690 (0.066μg/disc) increased Safranin O/Fast Green- and Masson’s Trichrome- stained cartilage matrix (Figure A), and decreased histology scores (p<0.05; Figure B), indicating reduced AF lamellar disorganization and fragmentation, larger NP area, increased number of NP cells and increased ECM vs. vehicle control. Radiographic measurement of disc height demonstrated significantly increased % DHI (p<0.05; Figure C), in SMO4690 treated rats compared to vehicle control, indicating an improvement in the disc health.

Conclusions: Wnt signaling plays a critical role in progression of DDD and NP cell differentiation and possibly disc regeneration. SMO4690, a small molecule Wnt pathway inhibitor promoted proliferation and differentiation of NP cells in vitro. In a pre-clinical rodent model for DDD, SMO4690 regenerated NP cells, cartilage matrix, improved disc height, health and shape compared to vehicle, with minimal exposure in plasma or systemic toxicity. These data suggested that SMO4690 has potential as a disease modifying therapy for DDD.
Category (Complete): Spine & Intervertebral Disc  
Keyword (Complete): Anulus Fibrosus; Degeneration; Animal Model; Cartilage Regeneration  
Presentation Preference (Complete): Podium Preference  
Additional (Complete):  
Type of Abstract (Required): Basic Science  
Are you age 40 or under and within 5 years of your research degree? (Required): No  
Do you want to be considered for a Need Based Travel Assistance Award? (Required): No

Payment (Complete): Your credit card order has been processed on Monday 21 November 2016 at 4:25 PM.  
Status: Complete  
Osteoarthritis Research Society International  
1120 Rt. 73, Ste. 200  
Mt. Laurel, NJ 08054, USA  
yconverse@oarsi.org

For any technical inquiries, click here to contact OASIS Helpdesk or call 217-398-1792.

Leave OASIS Feedback

Powered by oOASIS, The Online Abstract Submission and Invitation System SM  
© 1996 – 2016 CTI Meeting Technology All rights reserved.